Key finding

The first real-world study of radium-223 for metastatic castration-resistant prostate cancer finds a low rate of secondary malignancies and safety and overall survival consistent with the clinical trial experience .

Findings of this largely European international trial appeared in the Lancet .

Background and/or implications

Radium-223 is an ...